Jafron Biomedical Co Ltd Total Liabilities
Jafron Biomedical Co Ltd total liabilities. Based on the latest financial reports, Jafron Biomedical Co Ltd (300529) has total liabilities worth CN¥1.74 Billion CNY (≈ $254.12 Million USD) as of June 2026. Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities. Check Jafron Biomedical Co Ltd liquid asset ratio to evaluate the company's liquid asset resilience ratio.
Total Liabilities of Jafron Biomedical Co Ltd (2011–2025)
Total liabilities of Jafron Biomedical Co Ltd from 2011 to 2025. This chart illustrates how Jafron Biomedical Co Ltd's total liabilities have evolved over time, based on quarterly financial data. Explore 300529 long-term investments to assets to see how much of total assets are deployed in long-term investments.
Jafron Biomedical Co Ltd Competitors by Total Liabilities
The table below lists competitors of Jafron Biomedical Co Ltd ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
AviChina Industry & Technology Company Limited
F:AVT
|
Germany | €107.22 Billion |
|
Upstart Holdings Inc
NASDAQ:UPST
|
USA | $2.18 Billion |
|
West African Resources Limited
F:W25
|
Germany | €957.40 Million |
|
AF Gruppen ASA
OL:AFG
|
Norway | Nkr13.29 Billion |
|
ServisFirst Bancshares Inc
NYSE:SFBS
|
USA | $16.26 Billion |
|
Hanesbrands Inc
NYSE:HBI
|
USA | $3.83 Billion |
|
Adani Wilmar Limited
NSE:AWL
|
India | Rs-104.44 Billion |
|
Sineng Electric Co Ltd
SHE:300827
|
China | CN¥7.84 Billion |
Liability Composition Analysis (2011–2025)
This chart breaks down Jafron Biomedical Co Ltd's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted. For the complete balance sheet picture, see 300529 total assets.
Liquidity & Leverage Metrics
Jafron Biomedical Co Ltd Total Liabilities Ratios Explained
Jafron Biomedical Co Ltd total liabilities ratios compare its liabilities with its current assets, cash and shareholder equity.
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 2.11 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | 0.50 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 0.33 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how Jafron Biomedical Co Ltd's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for Jafron Biomedical Co Ltd (2011–2025)
The table below shows the annual total liabilities of Jafron Biomedical Co Ltd from 2011 to 2025.
| Year | Total Liabilities | Change |
|---|---|---|
| 2025-12-31 | CN¥1.94 Billion ≈ $283.54 Million |
-5.43% |
| 2024-12-31 | CN¥2.05 Billion ≈ $299.80 Million |
-14.29% |
| 2023-12-31 | CN¥2.39 Billion ≈ $349.79 Million |
+31.13% |
| 2022-12-31 | CN¥1.82 Billion ≈ $266.76 Million |
+27.80% |
| 2021-12-31 | CN¥1.43 Billion ≈ $208.74 Million |
+272.38% |
| 2020-12-31 | CN¥383.06 Million ≈ $56.05 Million |
+18.18% |
| 2019-12-31 | CN¥324.13 Million ≈ $47.43 Million |
-1.79% |
| 2018-12-31 | CN¥330.04 Million ≈ $48.30 Million |
+6.16% |
| 2017-12-31 | CN¥310.90 Million ≈ $45.49 Million |
+168.46% |
| 2016-12-31 | CN¥115.81 Million ≈ $16.95 Million |
-7.06% |
| 2015-12-31 | CN¥124.61 Million ≈ $18.23 Million |
+43.91% |
| 2014-12-31 | CN¥86.59 Million ≈ $12.67 Million |
+6.11% |
| 2013-12-31 | CN¥81.60 Million ≈ $11.94 Million |
+60.83% |
| 2012-12-31 | CN¥50.74 Million ≈ $7.42 Million |
+65.41% |
| 2011-12-31 | CN¥30.68 Million ≈ $4.49 Million |
-- |
About Jafron Biomedical Co Ltd
Jafron Biomedical Co.,Ltd. engages in the research, development, production, and sale of blood purification products for hemadsorption field worldwide. The company offers therapies for kidney, liver, and critical diseases, as well as poisoning. It also provides HA series disposable hemoperfusion cartridge; BS series disposable plasma bilirubin perfusion adsorption column; blood purification machi… Read more